Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Ironwood Pharmaceuticals, Inc.’s (IRWD - Analyst Report) second-quarter 2013 loss of 57 cents per share compared unfavorably with the year-ago loss of 38 cents per share. Results were primarily hurt by higher selling, general and administrative (SG&A) and collaboration expense. The Zacks Consensus Estimate hinted at a loss of 71 cents per share.

Total revenues in the second quarter of 2013 were down to $9.7 million from $14.6 million in the year-ago period. Revenues were above the Zacks Consensus Estimate of $8 million.

Linzess Update

We note that Ironwood’s sole marketed product is Linzess (linaclotide). It is marketed for the treatment (once-daily) of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Ironwood co-markets the drug with Forest Laboratories, Inc. (FRX - Analyst Report). Forest Labs and Ironwood share Linzess revenues generated in the U.S. equally. Net sales of the drug, as reported by Forest Labs, came in at $28.8 million in the second quarter of 2013 as compared to $4.5 million in the previous quarter.

We remind investors that on Dec 17, 2012, the companies announced the U.S. launch of Linzess. The launch followed the approval of the drug by the U.S. Food and Drug Administration (FDA) in Aug 2012.

The companies are looking to broaden the Linzess label by incorporating additional patient populations and indications. To further analyze the effect of Linzess on abdominal symptoms in patients suffering from CIC, Forest Labs and Ironwood Pharma have initiated a phase IIIb clinical trial. Results from the trial are expected in the third quarter of 2013. Forest Labs and Ironwood plan to evaluate the use of Linzess in the pediatric population and in opioid-induced constipation patients in the first half of 2014.

In the EU, approval came in Nov 2012 under the trade name Constella. Ironwood is collaborating with Almirall, S.A. in EU for the drug. The product is now available in Germany, the UK and the Nordic countries and is expected to be launched across Europe in 2013 and 2014.

Ironwood is also working with its Japanese partner, Astellas Pharma Inc. for the development of Linzess in Japan, South Korea, Taiwan, Thailand, the Philippines and Indonesia and with AstraZeneca (AZN - Analyst Report) in China. Currently, Astellas is evaluating it in a phase II trial for IBS-C with results expected this year. Ironwood and AstraZeneca expect to start enrollment in a phase III trial evaluating linaclotide in adult IBS-C patients in Aug 2013 with data expected in the first half of 2015.

Other Expenses

During the second quarter of 2013, SG&A expenses surged 53.6% to $30.9 million. The massive increase was primarily attributable to Linzess commercialization costs. For 2013, Ironwood continues to expect total investment in sales and marketing for Linzess in the range of $250 – $300 million.

Research and development (R&D) expenses amounted to $24.1 million, a decrease of 25.3%. In 2013, Ironwood continues to expect to invest approximately $60–$75 million in R&D expenses not pertaining to linaclotide.

Ironwood carries a Zacks Rank #3 (Hold) in the short run. We expect investor focus to remain on the market performance of Linzess. Stocks which currently look attractive in the pharma space include Cadence Pharmaceuticals Inc. , carrying a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%